Transenterix Inc (TRXC) Trading 21.1% Higher

Transenterix Inc (NASDAQ:TRXC) shares traded up 21.1% during trading on Monday . The stock traded as high as $3.03 and last traded at $2.87. 18,594,533 shares were traded during mid-day trading, an increase of 163% from the average session volume of 7,070,060 shares. The stock had previously closed at $2.37.

TRXC has been the topic of several recent analyst reports. Zacks Investment Research cut Transenterix from a “buy” rating to a “sell” rating in a report on Tuesday, August 8th. Stifel Nicolaus restated a “buy” rating and set a $4.00 price target (up from $3.75) on shares of Transenterix in a research report on Monday. Finally, Ladenburg Thalmann Financial Services set a $5.00 price target on Transenterix and gave the stock a “buy” rating in a research report on Friday, October 20th.

The firm’s market capitalization is $439.67 million. The firm has a 50-day moving average of $1.98 and a 200-day moving average of $1.04.

In other news, insider Todd Pope sold 600,000 shares of the firm’s stock in a transaction on Wednesday, October 18th. The stock was sold at an average price of $3.68, for a total value of $2,208,000.00. Following the completion of the sale, the insider now owns 462,644 shares of the company’s stock, valued at approximately $1,702,529.92. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Several institutional investors have recently bought and sold shares of TRXC. LMR Partners LLP acquired a new stake in shares of Transenterix in the 2nd quarter worth $189,000. Global X Management Co. LLC boosted its position in shares of Transenterix by 238.3% in the 2nd quarter. Global X Management Co. LLC now owns 331,075 shares of the company’s stock worth $235,000 after purchasing an additional 233,213 shares in the last quarter. Royal Bank of Canada boosted its position in shares of Transenterix by 17.1% in the 2nd quarter. Royal Bank of Canada now owns 418,867 shares of the company’s stock worth $298,000 after purchasing an additional 61,034 shares in the last quarter. UBS Oconnor LLC acquired a new stake in shares of Transenterix in the 2nd quarter worth $390,000. Finally, Goldman Sachs Group Inc. boosted its position in shares of Transenterix by 7,137.7% in the 2nd quarter. Goldman Sachs Group Inc. now owns 1,203,199 shares of the company’s stock worth $854,000 after purchasing an additional 1,186,575 shares in the last quarter.

ILLEGAL ACTIVITY WARNING: “Transenterix Inc (TRXC) Trading 21.1% Higher” was originally reported by Community Financial News and is the property of of Community Financial News. If you are accessing this piece on another publication, it was illegally copied and republished in violation of U.S. & international trademark and copyright laws. The original version of this piece can be viewed at https://www.com-unik.info/2017/11/01/transenterix-inc-trxc-trading-21-1-higher.html.

About Transenterix

TransEnterix, Inc is a medical device company. The Company is focused on the development and commercialization of ALF-X Surgical Robotic System (the ALF-X System), and SurgiBot System. The Company’s ALF-X System is a multi-port robotic surgery system, which allows multiple robotic arms to control instruments and a camera.

What are top analysts saying about Transenterix Inc? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Transenterix Inc and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit